IRB #

IRB00008158

Title

PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment

Principal Investigator

Stephen Chui

Study Purpose

To evaluate the safety and effectiveness of NeuVax (the study drug), in preventing the recurrence of node-positive, early stage breast cancer with low to intermediate HER2 expression.

Medical Condition(s)

Early stage breast cancer with low to intermediate HER2 expression

Eligibility Criteria

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

36 months of study drug doses and up to 10 years for follow-up

Minors Included

No

Contact

Deirdre Nauman, RN (503-494-3078)

Sponsor

Galena Biopharma

Recruitment End

Compensation Provided

No